Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]
Researchers at Purdue have developed what they have described as prostate cancer “homing device.” They believe that this treatment modality can improve detection, and allow for the first targeted treatment of prostate cancer. The researchers have synthesized a molecule that finds and penetrates only prostate cancer cells. They have also created imaging agents and therapeutic [...]
Men with advanced prostate cancer who develop an adrenal tumor will usually undergo laparoscopic adrenalectomy (removal of the adrenal gland) as a treatment method. Just like with prostate surgery. in some situations surgery might not be the best alternative for an individual man. An individual case was recently completed at the Department of Renal and [...]
There is a new study that shows that an alpha-particle emitting radiopeptide—radioactive material bound to a synthetic peptide, a component of protein—is effective for treating prostate cancer in mice, according to researchers. The conclusions of this study could eventually (still years away if it also works in men) result in a significant breakthrough in advanced [...]
The American Association of Cancer Researchers (AACR) is in the midst of its annual scientific research meeting in Denver Colorado. As interesting prostate cancer specific information becomes available I will try and share the news. One of the biggest concerns we face in prostate cancer is in deciding when a cancer needs to be treated. [...]
At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, National Cancer Institute (NCI) Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment. [...]
Our own Alvin Chin, Prostate Cancer Survivor & Advocate, Virginia Prostate Coalition, joins oncologists Howard Scher MD, Donald S. Coffey, PhD, Peter S. Nelson, MD and representatives from research and the Pharma industry for a round table discussion April 23. You can make your voice heard by joining the conference by phone and emailing questions [...]
Under the resources section of the blog I have just added the Memorial Sloan-Kettering Cancer Center prostate nomogram for PSA doubling and PSA velocity. Joel T Nowak MA, MSW
As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]
One of the significant secondary side effects resulting from of our advanced prostate cancer treatments can be blood clots. Blood clots are potentially dangerous as they can lead to heart attacks, strokes and death. Warfarin is one of the drugs commonly prescribed to prevent these dangerous blood clots from ever forming. However, dosing of Warfarin [...]
